SHANDONG BOAN BIOTECH.H 1 (F:UJ9) — Market Cap & Net Worth
Market Cap & Net Worth: SHANDONG BOAN BIOTECH.H 1 (UJ9)
SHANDONG BOAN BIOTECH.H 1 (F:UJ9) has a market capitalization of $392.89 Million (€336.06 Million) as of June 15, 2026. Listed on the F stock exchange, this Germany-based company holds position #13652 globally and #1400 in its home market, demonstrating a -6.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SHANDONG BOAN BIOTECH.H 1's stock price €0.54 by its total outstanding shares 622333694 (622.33 Million). Review SHANDONG BOAN BIOTECH.H 1 (UJ9) total liabilities to assess the company's total debt and financial obligations.
SHANDONG BOAN BIOTECH.H 1 Market Cap History: 2023 to 2026
SHANDONG BOAN BIOTECH.H 1's market capitalization history from 2023 to 2026. Data shows change from $1.50 Billion to $392.89 Million (-29.82% CAGR).
SHANDONG BOAN BIOTECH.H 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SHANDONG BOAN BIOTECH.H 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.78x
SHANDONG BOAN BIOTECH.H 1's market cap is 0.78 times its annual revenue
Latest Price to Earnings (P/E) Ratio
86.06x
SHANDONG BOAN BIOTECH.H 1's market cap is 86.06 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $1.50 Billion | $618.13 Million | -$119.38 Million | 2.42x | N/A |
| 2024 | $771.23 Million | $726.32 Million | $73.19 Million | 1.06x | 10.54x |
| 2025 | $614.80 Million | $784.82 Million | $7.14 Million | 0.78x | 86.06x |
Competitor Companies of UJ9 by Market Capitalization
Companies near SHANDONG BOAN BIOTECH.H 1 in the global market cap rankings as of June 15, 2026.
Key companies related to SHANDONG BOAN BIOTECH.H 1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #438 globally with a market cap of $63.06 Billion USD.
- UCB SA (BR:UCB): Ranked #544 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #563 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $444.93 |
| #438 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.06 Billion | $612.14 |
| #544 | UCB SA | BR:UCB | $49.68 Billion | €274.90 |
| #563 | Argen-X | BR:ARGX | $47.14 Billion | €783.60 |
SHANDONG BOAN BIOTECH.H 1 Historical Marketcap From 2023 to 2026
Between 2023 and today, SHANDONG BOAN BIOTECH.H 1's market cap moved from $1.50 Billion to $ 392.89 Million, with a yearly change of -29.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €392.89 Million | -36.09% |
| 2025 | €614.80 Million | -20.28% |
| 2024 | €771.23 Million | -48.54% |
| 2023 | €1.50 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 15th, 2026 the market cap of SHANDONG BOAN BIOTECH.H 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $392.89 Million USD |
| MoneyControl | $392.89 Million USD |
| MarketWatch | $392.89 Million USD |
| marketcap.company | $392.89 Million USD |
| Reuters | $392.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SHANDONG BOAN BIOTECH.H 1
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, … Read more